Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B

被引:74
作者
Gray, Elin Solomonovna
Meyers, Tammy
Gray, Glenda
Montefiori, David Charles
Morris, Lynn [1 ]
机构
[1] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa
[2] Univ Witwatersrand, Harriet Shezi Clin, Johannesburg, South Africa
[3] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pmed.0030255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A Phase I clinical trial has been proposed that uses neutralising monoclonal antibodies (MAbs) as passive immunoprophylaxis to prevent mother-to-child transmission of HIV-1 in South Africa. To assess the suitability of such an approach, we determined the sensitivity of paediatric HIV-1 subtype C viruses to the broadly neutralising MAbs IgG1b12, 2G12, 2F5, and 4E10. Methods and Findings: The gp160 envelope genes from seven children with HIV-1 subtype C infection were cloned and used to construct Env-pseudotyped viruses that were tested in a single-cycle neutralisation assay. The epitopes defining three of these MAbs were determined from sequence analysis of the envelope genes. None of the seven HIV-1 subtype C pseudovirions was sensitive to 2G12 or 2F5, which correlated with the absence of crucial N-linked glycans that define the 2G12 epitope and substitutions of residues integral to the 2F5 epitope. Four viruses were sensitive to IgG1b12, and all seven viruses were sensitive to 4E10. Conclusions: Only 4E10 showed significant activity against HIV-1 subtype C isolates, while 2G12 and 2F5 MAbs were ineffective and IgG1b12 was partly effective. It is therefore recommended that 2G12 and 2F5 MAbs not be used for passive immunization experiments in southern Africa and other regions where HIV-1 subtype C viruses predominate.
引用
收藏
页码:1023 / 1031
页数:9
相关论文
共 57 条
[41]   The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120 [J].
Sanders, RW ;
Venturi, M ;
Schiffner, L ;
Kalyanaraman, R ;
Katinger, H ;
Lloyd, KO ;
Kwong, PD ;
Moore, JP .
JOURNAL OF VIROLOGY, 2002, 76 (14) :7293-7305
[42]   Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design [J].
Saphire, EO ;
Parren, PWHI ;
Pantophlet, R ;
Zwick, MB ;
Morris, GM ;
Rudd, PM ;
Dwek, RA ;
Stanfield, RL ;
Burton, DR ;
Wilson, IA .
SCIENCE, 2001, 293 (5532) :1155-1159
[43]  
Scanlan CN, 2003, ADV EXP MED BIOL, V535, P205
[44]   The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on the outer face of gp120 [J].
Scanlan, CN ;
Pantophlet, R ;
Wormald, MR ;
Saphire, EO ;
Stanfield, R ;
Wilson, IA ;
Katinger, H ;
Dwek, RA ;
Rudd, PM ;
Burton, DR .
JOURNAL OF VIROLOGY, 2002, 76 (14) :7306-7321
[45]   A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 [J].
Stiegler, G ;
Kunert, R ;
Purtscher, M ;
Wolbank, S ;
Voglauer, R ;
Steindl, F ;
Katinger, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (18) :1757-1765
[46]   Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies [J].
Trkola, A ;
Kuster, H ;
Rusert, P ;
Joos, B ;
Fischer, M ;
Leemann, C ;
Manrique, A ;
Huber, M ;
Rehr, M ;
Oxenius, A ;
Weber, R ;
Stiegler, G ;
Vcelar, B ;
Katinger, H ;
Aceto, L ;
Günthard, HF .
NATURE MEDICINE, 2005, 11 (06) :615-622
[47]   Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 [J].
Trkola, A ;
Purtscher, M ;
Muster, T ;
Ballaun, C ;
Buchacher, A ;
Sullivan, N ;
Srinivasan, K ;
Sodroski, J ;
Moore, JP ;
Katinger, H .
JOURNAL OF VIROLOGY, 1996, 70 (02) :1100-1108
[48]  
Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
[49]   Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6 [J].
Verrier, F ;
Nádas, A ;
Gorny, MK ;
Zolla-Pazner, S .
JOURNAL OF VIROLOGY, 2001, 75 (19) :9177-9186
[50]   Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site [J].
VijhWarrier, S ;
Pinter, A ;
Honnen, WJ ;
Tilley, SA .
JOURNAL OF VIROLOGY, 1996, 70 (07) :4466-4473